12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Latuda lurasidone regulatory update

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary submitted 2 sNDAs to FDA for Latuda lurasidone to treat adult patients with depressive episodes associated with bipolar I disorder as a monotherapy and as an adjunctive...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >